Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $37.38
by Renee Jackson · The Cerbat GemShares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $37.3750.
Several analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Sutro Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Wells Fargo & Company raised shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $8.00 to $27.00 in a research note on Tuesday, March 24th. Truist Financial raised shares of Sutro Biopharma to a “strong-buy” rating in a research note on Wednesday, March 25th. HC Wainwright raised shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and upped their price objective for the company from $10.00 to $28.00 in a research note on Tuesday, March 24th. Finally, Citizens Jmp raised shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective for the company in a research note on Tuesday, January 20th.
View Our Latest Stock Report on STRO
Institutional Investors Weigh In On Sutro Biopharma
A number of institutional investors have recently made changes to their positions in the business. State of Tennessee Department of Treasury purchased a new stake in shares of Sutro Biopharma in the 4th quarter valued at $86,000. Jane Street Group LLC purchased a new stake in shares of Sutro Biopharma in the 4th quarter valued at $265,000. Bridgeway Capital Management LLC boosted its stake in shares of Sutro Biopharma by 232.6% in the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after purchasing an additional 30,000 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Sutro Biopharma by 51.3% in the 3rd quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock valued at $104,000 after purchasing an additional 40,488 shares in the last quarter. Finally, Shay Capital LLC boosted its stake in shares of Sutro Biopharma by 20.1% in the 3rd quarter. Shay Capital LLC now owns 312,051 shares of the company’s stock valued at $271,000 after purchasing an additional 52,162 shares in the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.
Sutro Biopharma Stock Performance
Sutro Biopharma stock opened at $28.78 on Friday. The firm’s fifty day moving average price is $21.50 and its 200-day moving average price is $14.40. The stock has a market cap of $476.88 million, a P/E ratio of -1.10 and a beta of 1.31. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $28.92.
About Sutro Biopharma
Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.
Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.